Cargando…

Long-Term Antithyroid Drug Treatment of Graves’ Disease in Children and Adolescents: A 20-Year Single-Center Experience

BACKGROUND/PURPOSE: Graves’ disease (GD) is the most common cause of thyrotoxicosis in children and adolescents. There is some debate regarding the optimal treatment and predicting factors of remission or relapse in children and adolescents with GD. In this study, we report a retrospective study of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Ari, Kim, Su Jin, Kim, Min-Sun, Kim, Jiyeon, Kim, Insung, Bae, Ga Young, Seo, Eunseop, Cho, Young Seok, Choi, Joon Young, Cho, Sung Yoon, Jin, Dong-Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236938/ https://www.ncbi.nlm.nih.gov/pubmed/34194397 http://dx.doi.org/10.3389/fendo.2021.687834

Ejemplares similares

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort
por: Jin, Meihua, et al.
Publicado: (2023)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
por: Kwon, Hyemi, et al.
Publicado: (2016)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves’ disease: a systemic review
por: Xie, Qingxing, et al.
Publicado: (2023)

Graves’ disease, its treatments, and the risk of atrial fibrillation: A Korean population-based study
por: Cho, Yoon Young, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center
por: Yang, Aram, et al.
Publicado: (2020)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea
por: Park, Hyojung, et al.
Publicado: (2021)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Safety of Antithyroid Drugs in Avoiding Hyperglycemia or Hypoglycemia in Patients With Graves’ Disease and Type 2 Diabetes Mellitus: A Literature Review
por: Hsieh, Yu-Shan
Publicado: (2023)

Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea
por: Kim, Hee Kyung, et al.
Publicado: (2015)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
por: Kim, Hyunsam, et al.
Publicado: (2018)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

Decreased Expression of Ileal Thyroid Hormone Transporters in a Hypothyroid Patient: A Case Report
por: Chung, Chae Won, et al.
Publicado: (2021)

Appropriate Age for Height Control Treatment in Patients With Marfan Syndrome
por: Kim, Sung Eun, et al.
Publicado: (2021)

The association between vitamin D supplementation and the long-term prognosis of differentiated thyroid cancer patients: a retrospective observational cohort study with propensity score matching
por: Ahn, Jong-hyuk, et al.
Publicado: (2023)

Clinical Significance of Classification of Graves’ Disease According to the Characteristics of TSH Receptor Antibodies
por: Kim, Won Bae, et al.
Publicado: (2001)

Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves’ Disease: A Nationwide Population-Based Cohort Study
por: Song, Eyun, et al.
Publicado: (2021)

MON-589 Prognostic Predictors of Initial Response of Graves' Disease to Antithyroid Drugs: A Single Center Experience
por: Alaghoury, Aliaa, et al.
Publicado: (2019)

Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease
por: Gill, Harinder, et al.
Publicado: (2010)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years
por: Cheng, Ying, et al.
Publicado: (2023)

Secular Trends in Ablation Therapy for Graves’ Disease: An Analysis of a 15-Year Experience at a Tertiary Hospital in South Korea
por: Kim, Min Joo, et al.
Publicado: (2021)

Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients
por: Cho, Yoon Young, et al.
Publicado: (2021)

Antithyroid Drug-Induced Agranulocytosis: A Case Report
por: MacKay, Micaela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cb7n5e1d7191gmff483n70adm0